<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643213</url>
  </required_header>
  <id_info>
    <org_study_id>A7006</org_study_id>
    <secondary_id>A7006</secondary_id>
    <nct_id>NCT01643213</nct_id>
  </id_info>
  <brief_title>Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate patient preference of the Boston Scientific
      Corporation (BSC) commercially approved spinal cord stimulation (SCS) systems with the
      Observational Mechanical Gateway (OMG) in patients who failed non-BSC SCS trial therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal cord stimulation (SCS) is an established therapy for the treatment of chronic pain of
      the trunk and/or limbs. Standard practice includes a screening trial, typically lasting from
      3 days to 7 days or more, for both the physician and the patient to evaluate whether SCS
      therapy is appropriate for permanent implantation. Screening trial success (hereafter
      referred to as a trial) is often considered predictive of long-term success of the therapy,
      although that has never been definitively demonstrated.

      Boston Scientific Corporation (BSC) developed the Observational Mechanical Gateway (OMG)
      connectors to allow patients who previously underwent an SCS trial using Medtronic or St Jude
      Medical leads, operating room cables (OR-cables), and external trial stimulators (ETSs), to
      be able to connect to BSC commercially approved Spinal Cord Stimulation (SCS) trial systems
      to evaluate the BSC SCS therapy in the physician office setting prior to removal of the
      non-BSC leads.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Treatment Preference</measure>
    <time_frame>30 minutes after activation of stimulation</time_frame>
    <description>Subject were asked if he/she prefers their current period SCS therapy over the SCS therapy he/she received during the SCS trial period prior to Baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>BSC approved SCS Trial Therapy w/ OMG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Boston Scientific SCS Trial Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non Boston Scientific SCS Trial Therapy</intervention_name>
    <description>No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain</description>
    <arm_group_label>Non Boston Scientific SCS Trial Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BSC approved SCS Trial Therapy w/ OMG</intervention_name>
    <description>No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain</description>
    <arm_group_label>BSC approved SCS Trial Therapy w/ OMG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic intractable pain of the trunk and/or lower extremities

          -  History of trunk and/or lower extremity pain lasting at least 6 months

          -  Study candidate completed a spinal cord stimulation (SCS) trial of a FDA-approved
             non-Boston Scientific Corporation (non-BSC) system, exclusively for the treatment of
             chronic intractable pain of the trunk and/or lower extremities, that will not proceed
             to permanent implantation due to unsatisfactory treatment or in the physician's
             opinion received sub-optimal results

          -  Currently implanted with FDA-approved non-BSC SCS lead(s) exclusively in the
             thoracolumbar epidural space that are temporarily anchored for non-surgical removal at
             the termination of the screening trial period and which are approved for use with
             either the Observational Mechanical Gateway (OMG) A or OMG-M, per the OMG directions
             for use

        Key Exclusion Criteria:

          -  Primary source of pain is cancer-related, pelvic, visceral or angina

          -  Investigator-suspected gross lead migration during the non-BSC trial period which may
             preclude the study candidate from receiving adequate SCS therapy

          -  Study candidate reports &lt;10% paresthesia coverage of overall pain while running the
             preferred stimulation settings on the non-BSC SCS system at the end of the non-BSC SCS
             screening trial period

          -  Study candidate unwilling to tolerate implantation with an SCS system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roshini Jain</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Scientific Clinical Research Information Toll Free Number</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2016</results_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment to Control</title>
          <description>Treatment (BSC SCS Therapy) followed by Control (non-BSC SCS Therapy)</description>
        </group>
        <group group_id="P2">
          <title>Control to Treatment</title>
          <description>Control (non-BSC SCS Therapy) followed by Treatment (BSC SCS Therapy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment to Control</title>
          <description>Treatment (BSC SCS Therapy) followed by Control (non-BSC SCS Therapy)</description>
        </group>
        <group group_id="B2">
          <title>Control to Treatment</title>
          <description>Control (non-BSC SCS Therapy) followed by Treatment (BSC SCS Therapy)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="11.71"/>
                    <measurement group_id="B2" value="56" spread="12.02"/>
                    <measurement group_id="B3" value="56.9" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment: United States</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject's Treatment Preference</title>
        <description>Subject were asked if he/she prefers their current period SCS therapy over the SCS therapy he/she received during the SCS trial period prior to Baseline</description>
        <time_frame>30 minutes after activation of stimulation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment to Control</title>
            <description>Treatment (BSC SCS Therapy) followed by Control (non-BSC SCS Therapy)</description>
          </group>
          <group group_id="O2">
            <title>Control to Treatment</title>
            <description>Control (non-BSC SCS Therapy) followed by Treatment (BSC SCS Therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Treatment Preference</title>
          <description>Subject were asked if he/she prefers their current period SCS therapy over the SCS therapy he/she received during the SCS trial period prior to Baseline</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1 Yes, Period 2 Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1 Yes, Period 2 No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1 No, Period 2 Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1 No, Period 2 No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 days post randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment to Control</title>
          <description>Treatment (BSC SCS Therapy) followed by Control (non-BSC SCS Therapy)</description>
        </group>
        <group group_id="E2">
          <title>Control to Treatment</title>
          <description>Control (non-BSC SCS Therapy) followed by Treatment (BSC SCS Therapy)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Information</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

